

Jun 11, 2021


## © Quality Control and Quality Assurance (Part 11 of Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-onset Type 1 Diabetes Mellitus)

In 1 collection

Stephen.Gitelman <sup>1</sup>, Jeffrey A. Bluestone<sup>2</sup>

<sup>1</sup>Professor of Clinical Pediatrics, Department of Pediatrics University of California, San Francisco Room S-679, Campus Box 0434, 513 Parnassus Avenue, San Francisco, CA 94143;

<sup>2</sup>Professor of Medicine, Pathology, Microbiology & Immunology, University of California, San Francisco, Campus Box 0540, 513 Parnassus Avenue San Francisco, CA 94143



**ABSTRACT** 

This is Part 11 of "Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-Onset Type 1 Diabetes Mellitus".

This clinical study is supported by JDRF. The aim of the collection is to determine whether imatinib will slow the progression of the autoimmune destruction of ß cells and lead to the preservation of C-peptide secretion in T1DM and to assess Diabetes-related objectives and safety of Imatinib in new-onset type 1 diabetes mellitus".

**ATTACHMENTS** 

dngubkeaf.pdf

DOI

dx.doi.org/10.17504/protocols.io.bvehn3b6

PROTOCOL CITATION

Stephen. Gitelman, Jeffrey A. Bluestone 2021. Quality Control and Quality Assurance (Part 11 of Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-onset Type 1 Diabetes Mellitus). **protocols.io** https://dx.doi.org/10.17504/protocols.io.bvehn3b6

COLLECTIONS (1)

Collection of Protocols and Guidelines for Safety and Efficacy of Imatinib for Preserving Betacell Function in New-onset Type 1 Diabetes Mellitus

KEYWORDS

Safety, Efficacy, Imatinib, Beta-cell function, New-Onset Type 1 Diabetes Mellitus

LICENSE

This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

CREATED

May 29, 2021

 LAST MODIFIED

Jun 11, 2021

## OWNERSHIP HISTORY

May 29, 2021 Urmilas

Jun 03, 2021 Stephen. Gitelman

PROTOCOL INTEGER ID

50345

PARENT PROTOCOLS

Part of collection

Collection of Protocols and Guidelines for Safety and Efficacy of Imatinib for Preserving Beta-cell Function in Newonset Type 1 Diabetes Mellitus

## **GUIDELINES**

The investigator is required to keep accurate records to ensure that the conduct of the study is fully documented. The investigator is required to ensure that all CRFs are completed for every participant entered in the trial.

The sponsor is responsible for regular inspection of the conduct of the trial, for verifying adherence to the protocol, and for confirming the completeness, consistency, and accuracy of all documented data.

The CRFs will be completed online via a web-based electronic data capture (EDC) system that has been validated and is compliant with Part 11 Title 21 of the Code of Federal Regulations. Study staff at the site will enter information into the electronic CRFs, and the data will be stored remotely at a central database. All elements of data entry (i.e., time, date, verbatim text, and the name of the person performing the data entry) will be recorded in an electronic audit trail to allow all changes in the database to be monitored and maintained in accordance with federal regulations.

Study staff will enter data from a study visit on the relevant eCRFs within 14 days following the visit or the time when data becomes available.